Form 10-Q Regulus Therapeutics For: Sep 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- BofA Securities Reiterates Buy Rating on Apple (AAPL)
- Shipping stocks on fire — but cracks are forming in the rate rally
Regulus Therapeutics (RGLS) Tops Q3 EPS by 12c
November 6, 2015 8:23 AM ESTRegulus Therapeutics (NASDAQ: RGLS) reported Q3 EPS of ($0.25), $0.12 better than the analyst estimate of ($0.37). Revenue for the quarter came in at $1.9 million versus the consensus estimate of $2.85 million.
For earnings history and earnings-related data on Regulus Therapeutics (RGLS) click here.
... More